Bayesian Capital Management, LP Alkermes Plc. Transaction History

Bayesian Capital Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $324,720 - $400,488	12,300 New	12,300 $332,000
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $445,588 - $524,308	16,400 New	16,400 $459,000
Q1 2023 May 15, 2023	BUY	$25.31 - $29.02 $354,340 - $406,280	14,000 New	14,000 $394,000
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $530,640 - $613,854	20,100 New	20,100 $599,000
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $361,659 - $527,408	-27,172 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$13.06 - $21.24 $73,136 - $118,943	5,600 Added 25.96%	27,172 $392,000
Q4 2019 Feb 14, 2020	BUY	$17.29 - $21.74 $372,979 - $468,975	21,572 New	21,572 $440,000
Q1 2019 May 14, 2019	SELL	$28.4 - $36.49 $352,330 - $452,694	-12,406 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$27.94 - $44.61 $42,077 - $67,182	1,506 Added 13.82%	12,406 $366,000
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $420,740 - $502,708	10,900 New	10,900 $463,000
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $198,744 - $251,664	-4,900 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$53.61 - $67.26 $262,689 - $329,574	4,900 New	4,900 $284,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.